ANI Pharmaceuticals insider gets stock award, withholds tax

ANI Pharmaceuticals senior vice president and general counsel Meredith Cook reported equity compensation activity in company stock.

Rhea-AI Filing Summary

ANI Pharmaceuticals senior vice president and general counsel Meredith Cook reported equity compensation activity in company stock. On February 26, 2026, Cook acquired 13,895 shares of common stock as a restricted stock award at $77.15 per share, which will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026. On February 28, 2026, 1,555 shares at $73.90 per share were disposed of through shares withheld for tax purposes in connection with the vesting of 3,040 previously granted restricted shares. After these transactions, Cook directly owned 79,890 shares of ANI Pharmaceuticals common stock.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Cook Meredith

Role SR. VP, GENERAL COUNSEL & SEC.

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	1,555	$73.90	$115K
Grant/Award	Common Stock	13,895	$77.15	$1.07M

Holdings After Transaction: Common Stock — 79,890 shares (Direct)

Footnotes (2)

1. F1. Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026.
2. F2. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,040 shares of restricted stock, the grant of which was previously reported.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did ANI Pharmaceuticals (ANIP) report for Meredith Cook?

Meredith Cook reported a restricted stock grant and a tax-related share withholding. She received 13,895 restricted shares on February 26, 2026, and 1,555 shares were withheld on February 28, 2026 to cover taxes on vesting restricted stock.

How many ANI Pharmaceuticals (ANIP) shares did Meredith Cook acquire in the latest Form 4?

Meredith Cook acquired 13,895 shares of ANI Pharmaceuticals common stock. The shares were granted as a restricted stock award on February 26, 2026 at $77.15 per share and will vest in four equal annual installments after that grant date.

Why were shares of ANI Pharmaceuticals (ANIP) disposed of in Meredith Cook’s Form 4?

The 1,555 disposed shares were withheld for tax purposes. They relate to the vesting of 3,040 previously granted restricted shares and were treated as a tax-withholding disposition, exempt under Rule 16(b)-3, rather than an open-market sale.

How many ANI Pharmaceuticals (ANIP) shares does Meredith Cook own after these transactions?

Meredith Cook directly owns 79,890 ANI Pharmaceuticals shares after the reported activity. This figure reflects the restricted stock grant of 13,895 shares and the withholding of 1,555 shares for taxes tied to vesting restricted stock.

How will Meredith Cook’s ANI Pharmaceuticals (ANIP) restricted stock award vest?

The 13,895-share restricted stock award will vest over four years. It vests in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026, subject to the award’s standard vesting conditions.

Were Meredith Cook’s ANI Pharmaceuticals (ANIP) transactions open-market buys or sells?

The reported transactions were an equity award and tax withholding, not open-market trades. One entry is a restricted stock grant, and the other is a tax-withholding disposition of 1,555 shares tied to vesting restricted stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/02/2026 - 05:57 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cook Meredith

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE MN 56623

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SR. VP, GENERAL COUNSEL & SEC.

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/26/2026		A(1)		13,895	A	$77.15	81,445	D
Common Stock	02/28/2026		F(2)		1,555	D	$73.9	79,890	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026.

2. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,040 shares of restricted stock, the grant of which was previously reported.

Remarks:

	/s/ Meredith W. Cook	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.